Diagnostic value of HRCT-Thorax for pandemic COVID-19 pneumonia in Pakistan by Qureshi, Abdul Rasheed et al.
77                                              Journal of Rawalpindi Medical College (JRMC); 2020; 24 COVID-19 Supplement-1: 77-84 
Original Article 
 
Diagnostic value of HRCT-Thorax for pandemic COVID-19 
pneumonia in Pakistan 
Abdul Rasheed Qureshi1, Zaheer Akhtar2, Muhammad Irfan3, Muhammad Sajid4, Zeeshan Ashraf5 
1,3 Pulmonologist, Department of Pulmonology, Gulab 
Devi Teaching Hospital, Lahore.  
2 Professor, Department of Pulmonology, Gulab Devi 
Teaching Hospital, Lahore. 
4 Medical Officer, Gulab Devi Teaching Hospital, Lahore. 
5 Lecturer, Department of Statistics, Gulab Devi 
Educational Complex, Lahore. 
 
Author`s Contribution 
1 Conception of study  
1,3,4 Experimentation/Study conduction  
3,4 Analysis/Interpretation/Discussion  
1,2,3,5 Manuscript Writing 
2,5 Critical Review 
2,4,5 Facilitation and Material analysis 
Corresponding Author 
Dr. Muhammad Irfan 
Pulmonologist,  
Department of Pulmonology,  




Received:  25/7/2020 
Accepted:  06/8/2020 
 
 
Cite this Article: Qureshi, A.R., Akhtar, Z., Irfan, M., 
Sajid, M. & Ashraf, Z.(2020). Diagnostic value of 
HRCT-Thorax for pandemic COVID-19 pneumonia in 
Pakistan. Journal of Rawalpindi Medical College, 24 
COVID-19 Supplement-1, 77-84.  
DOI: https://doi.org/10.37939/jrmc.v24iSupp-1.1443 
    Conflict of Interest: Nil 







Background: In the scenario of, inadequate testing, the low sensitivity of the COVID-19-PCR test, limited 
availability of testing kits, and low detection rate, we aimed to investigate the usefulness of high-resolution 
computed tomography of chest (HRCT) for diagnosing pandemic coronavirus (COVID-19) pneumonia. 
Objective: To determine the diagnostic efficacy of HRCT thorax in Covid-19 pandemic pneumonia. 
Materials and Methods: This prospective, cross-sectional study was conducted in the Pulmonology–OPD of 
Gulab Devi Teaching Hospital, Lahore-Pakistan from 01-04-2020 to 15-07-2020.   121 patients with dry cough, 
fever, and dyspnea of sudden onset were included while patients with Bronchial Asthma, ILD, Tuberculosis, 
Bronchiectasis, COPD, and overt heart failure were excluded. Patients were investigated with chest x-ray, HRCT, 
COVID-PCR, and hematological tests. HRCT films were evaluated by a qualified and experienced radiologist. 
Findings were summarized, organized and statistical analysis was done by using SPSS-26 software to make an 
inference. 
Results: Five patients were diagnosed as non-covid. Out of 116-diagnosed covid-19 patients, 38(32.75%) showed 
sub-pleural consolidation, 19(16.37%) consolidation with air-bronchogram, 29(25.0%) crazy paving sign, one 
pleural effusion (0.86%) and 18 cases (15.51%) displayed reticulations. 11cases(9.48%) had isolated ground glass 
appearances, while all categories showed it to variable extent. 65 patients (56.03%) were PCR-positive while  
51(43.96) patients with positive-HRCT findings for COVID-19 pneumonia had negative nasopharyngeal-PCR. 
HRCT-Thorax revealed sensitivity: 97.41 %, specificity: 80%, PPV: 99.12%, NPV: 57.14%, and diagnostic accuracy 
of 96.69% for COVID-19 pneumonia. 
Conclusion: HRCT-Thorax, having high sensitivity and adequate specificity, can provide foundations for 
evidence-based early diagnosis and quantification of coronavirus pneumonia.  It can be tremendously useful for 
decision making in   PCR-negative patients and anticipating respiratory improvement or decline by serial scans. 
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Introduction 
 
The first case of coronavirus pneumonia was noticed 
in Wuhan, China in December 2019 and was later on 
recognized as coronavirus disease 2019 (COVID-19).1 
This epidemic spread worldwide like wildfire. WHO 
(World Health Organization) declared it as a Public 
Health Emergency of International Concern (PHEIC).2 
This disease is highly contagious and the number of 
cases multiplied rapidly over the globe. Current 
literature suggests that one infected patient may lead 
to more than two new patients.3 Some-times,  the 
disease is too drastic to be controlled and the outcome 
is a disaster only. 
This disease has challenged almost all fields of 
medicine and has affected not only the public rather 
very senior health care providers and eminent figures 
from the society have been lost to this lethal disease. 
At the mid of July, we are having 255,769 confirmed 
cases and 5,386 mortalities in the country, indicating 
the load and damage caused by this fatal disorder. The 
presentation of COVID-19 disease ranges from mild to 
an extensive disease requiring mechanical ventilation. 
Early diagnosis is crucial for the good management 
and effective control to preclude further 
dissemination.  
Usually patient presents with fever, dry cough, 
shortness of breath, and body aches and pains. The 
severity and acuteness of the symptoms, coupled with 
the propensity for an abrupt decline in respiratory 
function, necessitates the need to measure the 
magnitude of pulmonary involvement. 
Nasopharyngeal-PCR is the gold standard for 
diagnosis but its availability and sensitivity are quite 
low, around 60%. About 30-40% of cases are missed by 
this technique due to a high false-negative rate.4 
Furthermore, this test is not capable of calculating the 
magnitude and expected respiratory decline in 
patients. Chest  X-ray PA view is limited in its ability 
to detect the early involvement of lung with COVID-
19 infection.5 In contrast, HRCT-Thorax has been 
reported as a good tool for evidence-based diagnosis 
in the current epidemic, providing immediate results 
with high sensitivity and adequate specificity for 
COVID-19 pneumonia and the extent of pulmonary 
disease.6-7 HRCT-thorax can play a pivotal role by 
identifying the early phase lung infection and have 
been recommended as major evidence for clinical 
diagnosis in China.8 
Current researchers have reported the sensitivity of 
HRCT for COVID-19 infection more than 90% as 
compared to PCR  around 60-70%. According to 
WHO, HRCT can be very useful in determining the 
diagnosis, progression, and severity of the COVID-19 
disease.9-10 The use of HRCT in Pakistan is very limited 
due to profound fear, contagiousness & inadequate 
understanding and is tried only in selected cases.11-12 
The Chinese literature is rich in evidence, advocating 
the use of HRCT-thorax while the European, British 
and American radiological societies which were not 
recommending this modality in the beginning, are 
changing their statements about the use of HRCT.13-15 
Radiological Society of Pakistan has also suggested, 
the appropriate use of CT scan in selected patients as a 
tool to triage, in the background of increased incidence 
of COVID-19 symptomatic patients.16 
 
Materials and Methods 
 
This prospective study was conducted in 
Pulmonology-OPD of Gulab Devi Teaching Hospital, 
Lahore. (A 1500 bed-tertiary care hospital in the 
capital city of Punjab province). Ethical approval was 
obtained from the IRB of the hospital vide:  No. 
Admin/GDEC/20/325. After informed consent, 121 
OPD patients, from 1st April 2020 to 15 July 2020 with 
a presumptive clinical diagnosis of COVID-19 
infection were included. History of dry cough, fever, 
and shortness of breath of sudden onset were the main 
complaints while patients with Bronchial Asthma, 
ILD, Tuberculosis, Bronchiectasis, COPD, and overt 
heart failure were excluded.  All patients underwent 
routine hematological tests including white blood cell 
count, lymphocyte count, and hypersensitive C-
reactive protein tests. The patients were subjected to 
an X-ray chest PA view, HRCT thorax, ECG, and 
echocardiography. The x-ray chest (CXR) & HRCT 
images were evaluated by a qualified radiologist with 
20 years of experience at least. CXR was analyzed for 
haze and ill-defined consolidations with bilateral 
involvement. HRCT films were evaluated for 
radiological morphology and distribution patterns. 
ECG & Echocardiography explored cardiac status. All 
patients underwent the COVID-19 PCR-test by 
nasopharyngeal sample. Imaging findings, 
demographic and clinical data of the 121 patients were 
recorded on a preformed form. Sensitivity, specificity, 
and diagnostic accuracy were calculated by 
considering nasopharyngeal-PCR as a gold standard. 
Diagnostic yield was calculated on clinical,   PCR, and 
HRCT grounds independently. Data was organized, 
summarized, tabulated and bio-statistical analysis was 
79                                              Journal of Rawalpindi Medical College (JRMC); 2020; 24 COVID-19 Supplement-1: 77-84 
done to conclude. For statistical analysis, SPSS-26 soft-
ware was utilized. Quantitative data were described 
by + SD and categorical variables were expressed by 
frequency (percentage). Fissure exact test was used for 





This study included 121 patients age 18 to 67 years. 
The mean age was 42.64 years ± SD 17.62. Male gender 
was noted in 67 patients while 54 patients were 
female, male to female ratio was 1.2. All patients had 
contact history from their familial clusters.  Patients 
presented with typical respiratory complaints (Table-
I).  56 cases (46.28%) were above the age of 50 years, 
obesity was found in 13 cases (10.74%), Cigarette 
smoking 39 (32.23%) and Diabetes Mellitus (DM) was 
found in 39 cases (32.23%). 79 patients (65.28%) had 
elevated levels of CRP with mean 8.7 + SD 6.2 mg/dl. 
Only 65 patients (53.71%) were positive for COVID-19 
PCR-Test. HRCT findings were consistent with 
COVID-19 in 113 patients while it was unremarkable 
for 03 patients.  
Five patients, diagnosed as Non-COVID-19, consisted 
of ABPA (Allergic Broncho-pulmonary Aspergillosis) 
and Bacterial pneumonia two cases each and one case 
was diagnosed NSIP by correlation with 
clinicopathological data.   
 







The radiological morphology and radiographic 
appearance are described by Figure 1 and Figure 2. 
Not even a single case of cavitation or pneumothorax 
was found in 116 cases. Disease distribution pattern is 







Table 2: Frequency of symptoms in 121 Patients 





1. Unilateral 00 00 
2. Bilateral 121 100 
3.  Predominant right 
lung 
57 47.10 
4.  Predominant left lung 38 31.40 
5. Symmetrical bilateral 26 21.48 
6. Upper part  
predominant 
26 21.48 
7. Lower part 
predominant 
95 78.51 
8. Central lesions 35 28.93 
9. Peripheral lesions 86 71.07 
10. Scattered  lesions 11 9.09 
n = 121 
 
 
Figure 1: HRCT-morphology of 116 COVID-19 
patients. 













2.  Dry cough 67 55.37 
3. Shortness of 
breath 
109 90.08 
4. Muscle pain and 
weakness 
99 81.81 
5. Vague Chest 
pain 
34 28.09 
6.  Flu-like 
symptoms 
21 17.35 
7. No symptoms 12 9.91 
80                                              Journal of Rawalpindi Medical College (JRMC); 2020; 24 COVID-19 Supplement-1: 77-84 
 
  
A B  C  D  
*Plain X-ray and HRCT Features  
  
 
E F G H 
   
 
I J K L 
    
M N O P 
Figure 2: Common Radiological Morphologies in COVID-19 Pulmonary Infection 
*A: Patchy ill-defined consolidations, B: Bilateral haze, C: Bilateral Reticulations, D: Diffused GGO (coronal scan), 
E: Multifocal GGO, F: Basal GGO, G: Focal GGO, H & I: multifocal sub-pleural consolidation, J: Crazy paving 
sign, K&L: Peripheral multi-focal consolidations + Reticulations, M&N: Peripheral consolidation, O: 
Consolidation with air-bronchogram, P: Reticulations with minimal GGO. 
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Calculations: 
1. Total number of included patients= 121   
2. Number of cases diagnosed as non-COVID     
= 05 
3. Clinically proven cases of COVID-19= 116 
4. A number of Covid-19 cases were indicated by 
CXR.  = 86  
5. Number of cases diagnosed by 
nasopharyngeal-PCR = 65  
6. Number of cases diagnosed on HRCT findings 
= 113  
The sensitivity of PCR = 65/116 X100 =56.03% 
The sensitivity of CXR = 86/116 x 100 =74.13 % 
The sensitivity of HRCT = 113/116 x 100 = 97.41% 
Considering PCR as gold standard diagnostic test, 
TP=65, FN=51, TN=05, FP = 00 
The calculated efficacy result is shown in Table 3. 
Similarly, if HRCT is considered a new diagnostic test 
for COVID-19 pneumonia, we have TP=113, FN = 03, 
TN = 04, FP=1, the calculated efficacy is depicted in 
Table 3. 
TP: True positive, FP: False positive, TN: True 
Negative, FN: False Negative. 
 
Table 3: Diagnostic Efficacy of PCR & HRCT for 
COVID-19 Pneumonia 
Biostatistics for the efficacy of PCR 
Statistic Value 95% Confidence 
interval 
Sensitivity 56.03% 46.52% to 65.24% 
Specificity 100.00% 47.82% to 100.00% 
PPV  100.00%   
NPV  8.93% 7.39% to 10.75% 
Diagnostic 
Accuracy 
57.85% 48.54% to 66.77% 
Biostatistics for the efficacy of HRCT-Thorax 
Sensitivity 97.41% 92.63% to 99.46% 
Specificity 80.00% 28.36% to 99.49% 
PPV   99.12% 95.14% to 99.85% 
NPV 57.14% 28.66% to 81.57% 
Diagnostic 
Accuracy 
96.69% 91.75% to 99.09% 
PPV: Positive predictive value and NPV: Negative 
predictive value. 
The Fisher Exact Test statistic values = 0.0006 which is 






This study showed that the age range of 121 patients 
was from 18 to 67 years with a mean age of 42.64 years 
(± SD 17.62) which is comparable with the report of 
Qiongjie Hu and co-authors about Chinese population, 
with mean age 39.2 years + SD 9.6.17 We had 67 male 
(55.37%) and 54 female (44.62%) patients and male to 
female ratio was 1.2. The male gender preponderance 
is in agreement with the published studies of Badawi 
A, Ryoo SG and Channappanavar R, and co-authors.18-
19 This reduced susceptibility of females to COVID-19 
infection could be due to the protection from X 
chromosome and sex hormones, providing innate and 
adaptive immunity.20 
In this study, 46.28% of patients found above the age 
of 50 years, shows that this age can be a relative risk 
factor for the disease. Similarly, 39 cases (32.23%) with 
Cigarette smoking, 39 cases (32.23%) with Diabetes 
Mellitus (DM), and 13cases (10.74%) with Obesity 
were identified as co-morbidities (39+39+13=91) which 
is a significant number. Current literature has 
described the comorbidity induced increased risk of 
disease and mortality in viral pneumonia.21-22 
Out of 116, only 65patients (56.03%) were diagnosed 
with COVID-19 infection by PCR while 51 cases 
(43.96%) were not identified by the gold standard test. 
It means, if the PCR test report is negative, nobody can 
claim with confidence that patient is COVID-19 free, 
because of poor sensitivity and a high false-negative 
rate of the test.  The availability, virus specificity, 
quality of the testing kits, and under-testing due to 
resource limitations may be responsible factors for 
disease multiplication & dissemination in the 
community. But the good news here is that the 
virulence of virus in Pakistani population appears to 
be relatively weak because the number of patients 
with severe disease is low while we have abundant 
patients with mild to moderate, COVID-19 
pneumonia.   
It is also worth mentioning that not every patient 
requires mechanical ventilation on the first day of 
infection. It takes adequate time for transition from 
mild to severe COVID disease. The track of transition 
from mild to severe disease can be blocked by early 
diagnosis and prompt management.   Because this 
virus is highly contagious a very much unpredictable 
in behavior, its control needs early diagnosis for 
timely isolation or quarantine.  In these circumstances, 
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there is an urgent need for some alternative high 
sensitivity test, capable of capturing the disease 
untimely, for achieving good control in population.  
On the other hand, 87/116 patients were identified by 
x-ray chest (CXR) with a sensitivity of 75.0%. 
Although diagnostic yield is better than that of the 
gold standard (PCR) 25.0% patients were missed, 
while abnormal findings were noted on HRCT images 
of the same patients which are in agreement with the 
report of Van der Bruggen-Bogaarts BA1, Van der 
Bruggen HM.23  
The current study showed that HRCT thorax 
diagnosed viral pneumonia in 113 out of 116 cases 
with a sensitivity of 97.41%. Although it furnishes 
specific signs regarding COVID-19 pneumonia, it is 
not considered as specific as PCR, but according to the 
principles of differential diagnosis, we should always 
think about common issues. In the current on-going 
epidemic milieu, COVID-19 infection is the 
commonest issue, so HRCT can be utilized with 
confidence for its diagnosis.  
This study exhibited that both lungs were affected in 
100% cases, the predominant affected part was the 
lower zone in 78.51 % of patients. GGO was the 
earliest and the commonest (82.75% cases) sign on 
HRCT. Out of 96 cases, 11 cases (11.45%) showed 
isolated GGO scattered in lung fields, 38/96 cases 
(39.58%) were associated with consolidation, and 
29/96 cases (30.20%) were part of the crazy paving 
sign. Modern literature shows that in COVID-19 
pneumonia, type II alveolar epithelial cell injury, 
proteinaceous exudate, focal hyperplasia of 
pneumocytes and patchy inflammatory cellular 
infiltration, contribute to this GGO.24-26 
Consolidation was noted in 57cases, 38/57 cases 
(66.67%) showed sub-pleural, multifocal consolidation, 
and 19/57 cases (33.33%) were associated with the air-
bronchogram sign. All cases displayed GGO to a 
variable extent. These findings are very much 
comparable with the published report of Cheng Z, Lu 
Y and co-authors.27   
When septal thickening occurs in addition to GGO, 
crazy paving appearance is manifested on HRCT 
which is found in moderate to severe COVID-19 
Pneumonia. This study communicated   29 cases 
(25.0%) with this morphology while X. He, J. Zheng 
Dr., and co-workers have also described 25.0% of 
patients with the crazy paving sign.28 These patients 
pose a practical challenge because of having a 
potential of transition into serious disease and 
anticipated mechanical ventilation, in the future. 
Many precious lives have been lost to this pattern.29  
We found only one case of pleural effusion in this 
study which was bilateral and cardiogenic, secondary 
to coronary bypass surgery with superimposed 
COVID-19 infection. Otherwise, pleural effusion is not 
a common sign of this disease. But Huang et al. 
reported that pleural effusion may be noted in severe 
COVID-19 pneumonia.30 
This study displayed the efficacy of HRCT-thorax as 
sensitivity: 97.41 %, specificity: 80%, PPV: 99.12 %, 
NPV: 57.14%, diagnostic accuracy: 96.69 % for 
pulmonary Covid-19 disease. The detailed efficacy of 
COVID-PCR is described in table-III.  The p-value of 
0.0006 is < 0.05 and is highly significant, showing a 
remarkable difference between the diagnostic 
potential of the two modalities. This value indicates 
that HRCT has excellent capabilities of diagnosing 
COVID-19 pulmonary disease in an epidemic.  
According to the current literature, the sensitivity of 
PCR is as low as 60%.31 False-negative results can 
create the risk of inadvertent contamination of non-
COVID-19 patients, wards, and the community. Lower 
respiratory symptoms require tracheal aspirates or 
BAL (broncho-alveolar lavage) for maximum 
diagnostic yield but there is a very high risk of 
aerosolization & disease transmission to healthcare 
workers during these procedures.32 While HRCT is 
free of such drawbacks and was widely used in China 
as a diagnostic tool for COVID-19 pulmonary disease. 
HRCT can give rapid and valuable information for 
triaging isolation, and treatment procedures. It also 
determines the extent of lung involvement and is of 
tremendous help in anticipating the risk of rapid 
respiratory decline. No doubt, performing HRCT for 
every respiratory patient is neither cost-effective nor 
long-term sustainable. But this modality can be used 
during an epidemic, especially where high sensitivity 
reliable laboratory testing tool for COVID-19 is not 
available.  
In summary, HRCT features of COVID-19 pneumonia 
include ground-glass opacity, multi-focal, sub-pleural 
& basal consolidation, and crazy paving sign. 
Reticulation is found in patients with 2-3 weeks of 
history. We hope, the current study findings can 
facilitate early identification and good management of 
symptomatic and suspected COVID-19 pneumonia 
cases by adequate use of HRCT thorax, under 
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Limitations 
 
The main limitation of our study is that it is a single-
center study performed on limited sample size (121), 
so the study may not reflect a full range of radiological 
morphology and distribution pattern of COVID-19 
pulmonary disease. To additionally elucidate, a study 
with larger sample size or preferably, a multi-center 
study can further explore the radiological behavior of 
the disease. The 15.51% cases with reticulations found 
in the current study need further interpretation by a 
longitudinal study whether these reticulations are 
going to resolve completely or going to develop into a 




HRCT thorax, having excellent sensitivity and 
significant specificity for COVID-19 pulmonary 
infection, is a superb modality. It can play a positive 
role in early detection, quantification, and 
management of pulmonary coronavirus disease 
during a pandemic. If available, can be used with 
confidence for a re-evaluation of PCR-negative suspect 
for decision making about treatment and anticipating 
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